Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -186,566 | -402,727 | -197,611 | -302,139 | -245,874 |
| Depreciation Amortization | 13,109 | 2,325 | 16,897 | 7,531 | 8,266 |
| Income taxes - deferred | N/A | 2,140 | N/A | -16,246 | N/A |
| Accounts receivable | 9,840 | -20,104 | -7,583 | -5,172 | N/A |
| Accounts payable and accrued liabilities | 26,853 | 13,312 | N/A | N/A | 2,502 |
| Other Working Capital | 104,663 | -19,459 | -24,790 | -3,985 | 26,302 |
| Other Operating Activity | -100,119 | 79,130 | -77,479 | 66,168 | 47,829 |
| Operating Cash Flow | $-132,220 | $-345,383 | $-290,566 | $-253,843 | $-160,975 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -172,441 | 26,132 | -199,577 | 201,079 | 101,305 |
| PPE Investments | -43,905 | -24,832 | -4,076 | -2,793 | -10,188 |
| Net Acquisitions | N/A | N/A | N/A | -142,804 | N/A |
| Purchase Of Investment | -37,062 | -14,339 | N/A | N/A | N/A |
| Sale Of Investment | 79,842 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -5,555 | 0 | 170,322 | 0 | 0 |
| Investing Cash Flow | $-179,121 | $-13,039 | $-33,331 | $55,482 | $91,117 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -4,944 | N/A |
| Common Stock Issued | 600,508 | 365,072 | 336,853 | 141,211 | 138,676 |
| Other Financing Activity | -236 | 314,234 | 0 | 0 | 0 |
| Financing Cash Flow | $600,272 | $679,306 | $336,853 | $136,267 | $138,676 |
| Exchange Rate Effect | 1,119 | -165 | -472 | 528 | -65 |
| Beginning Cash Position | 436,244 | 115,525 | 103,041 | 164,607 | 95,854 |
| End Cash Position | 726,294 | 436,244 | 115,525 | 103,041 | 164,607 |
| Net Cash Flow | $290,050 | $320,719 | $12,484 | $-61,566 | $68,753 |
| Free Cash Flow | |||||
| Operating Cash Flow | -132,220 | -345,383 | -290,566 | -253,843 | -160,975 |
| Capital Expenditure | -43,905 | -24,832 | -4,076 | -2,793 | -10,188 |
| Free Cash Flow | -176,125 | -370,215 | -294,642 | -256,636 | -171,163 |